Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 20.
doi: 10.1038/s41551-025-01423-7. Online ahead of print.

A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases

Affiliations

A deep generative model for deciphering cellular dynamics and in silico drug discovery in complex diseases

Yumin Zheng et al. Nat Biomed Eng. .

Abstract

Human diseases are characterized by intricate cellular dynamics. Single-cell transcriptomics provides critical insights, yet a persistent gap remains in computational tools for detailed disease progression analysis and targeted in silico drug interventions. Here we introduce UNAGI, a deep generative neural network tailored to analyse time-series single-cell transcriptomic data. This tool captures the complex cellular dynamics underlying disease progression, enhancing drug perturbation modelling and screening. When applied to a dataset from patients with idiopathic pulmonary fibrosis, UNAGI learns disease-informed cell embeddings that sharpen our understanding of disease progression, leading to the identification of potential therapeutic drug candidates. Validation using proteomics reveals the accuracy of UNAGI's cellular dynamics analysis, and the use of the fibrotic cocktail-treated human precision-cut lung slices confirms UNAGI's predictions that nifedipine, an antihypertensive drug, may have anti-fibrotic effects on human tissues. UNAGI's versatility extends to other diseases, including COVID, demonstrating adaptability and confirming its broader applicability in decoding complex cellular dynamics beyond idiopathic pulmonary fibrosis, amplifying its use in the quest for therapeutic solutions across diverse pathological landscapes.

PubMed Disclaimer

Conflict of interest statement

Competing interests: N.K. served as a consultant to Pliant, Astra Zeneca, Veracyte, Augmanity, CSL Behring, Splisense, Galapagos, Fibrogen, GSK and Merck over the past 3 years, reports Equity in Pliant and Thyron, and grants from Veracyte, Boehringer Ingelheim, BMS and Astra Zeneca. The other authors declare no competing interests.

Update of

References

    1. Mitchell, K. J. What is complex about complex disorders? Genome Biol. 13, 237 (2012). - PubMed - PMC - DOI
    1. Schork, N. J. Genetics of complex disease: approaches, problems, and solutions. Am. J. Respir. Crit. Care Med. 156, S103–S109 (1997). - PubMed - DOI
    1. Ramsay, R. R., Popovic-Nikolic, M. R., Nikolic, K., Uliassi, E. & Bolognesi, M. L. A perspective on multi-target drug discovery and design for complex diseases. Clin. Transl. Med. 7, 3 (2018). - PubMed - PMC - DOI
    1. Iyengar, R. Complex diseases require complex therapies. EMBO Rep. 14, 1039–1042 (2013). - PubMed - PMC - DOI
    1. Dickson, M. & Gagnon, J. P. Key factors in the rising cost of new drug discovery and development. Nat. Rev. Drug Discov. 3, 417–429 (2004). - PubMed - DOI

LinkOut - more resources